Australia's largest stock trading and investment forum Australia's #1 stock forum

GMV

Click for more information

0.00%

3.9¢ g medical innovations holdings limited

GMVD Nasdaq, page-65

First 65 Last

Share
Profile

Follow
HonyakuKonyaku

662 Posts.

332

12/09/21

13:45

Post #: 56001849
Share

Originally posted by Galilee13: ↑

Hi HonyakuKonyaku

You raise another interesting point, and in general is more about the BS fluffy announcements Gmed has made during its life. All talk and no substance.

In regards to the university hospitals deal, I have been pushing Gmed on this for quiet sometime. As we all know this was to increase patient numbers three fold or by about 84,000 per year. On my numbers and using an average patient price of $220, this deal alone could be generating about $18m a year in revenue. Gmed also put out a release back in August stating that the IDTF business processed 4,000 patients during the month of July 2020. Again using an average price of $220, by the companies own announcements that’s $880k a month or $10m a year in revenue.

We all know this has turned out to be complete BS. So what happened?

After many emails to Gmed staff and directors I finally got a response from the Chairman Kenneth Melani who stated that the university hospitals deal and all the other distribution agreements were subject to raising additional capital from the Nasdaq IPO. Basically Gmed had no capital to execute these deals. He pointed me to the balance sheet and $650k c note deal in April that the company had no money to fund growth.

So, IMO don’t expect revenue to increase when the company releases June 30 numbers. The best we can hope for is an update on these deals and agreements. Now the company has the capital, as per Kenneth, the company should be able to execute these deals. This is evident from the fact the prizma is available on the Livecare website and network. He also pointed me to the FWP and the fact the company is using the IPO funds to growth the business vis the university hospitals deal, Livecare and Oschsner Health. All are mentioned in the F1.

I have also been communicating with the new IR Kevin. He tells me that the company will not be holding a conference call and the update “may” include an update on business activities. He also tells me Gmed is targeting some healthcare investor conferences in September.

Again, it’s all talk until we see come cash in the bank. I remain hopefully that the company has pull a rabbit out of a hat and increase revenue. If it can we should see a significant rerate of the share price just in time for pie shares to come out of restriction.

Expand

Thanks for sharing your hard won information Galilee. Melani's explanation still doesn't explain how 10 hospitals could be fully 'implemented' i.e. onboarded and generating revenue starting progressively from July 2020 yet there was not enough money for growth. Why wasn't this infusion of revenue enough to fund expansion? Also, the expansion had already kind of happened with the initial 10 hospitals going live. It seems like the July 2020 announcement of 4 hospitals already generating revenue and the August 2020 announcement of an increase to 10 generating revenue were simply not true and probably an attempt to get the first IPO over the line. No conference call means no awkward questions.

GMV Price at posting: 3.9¢ Sentiment: None Disclosure: Held
8 Upvote

1 Great analysis

Reply

Top Stories

USL

'Joaquin Silver District' acquisition to become a key asset for Unico

INA

Ingenia shares jump 7% on strong revenue and earnings figures

UNT

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Banking on ANZ in this week's Hot Stock tips

There are more pages in this discussion • 763 more messages in this thread...

First 65 Last

Add GMV (ASX) to my watchlist

SPONSORED BY